1. Home
  2. SRPT vs RGLS Comparison

SRPT vs RGLS Comparison

Compare SRPT & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • RGLS
  • Stock Information
  • Founded
  • SRPT 1980
  • RGLS 2007
  • Country
  • SRPT United States
  • RGLS United States
  • Employees
  • SRPT N/A
  • RGLS N/A
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • RGLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SRPT Health Care
  • RGLS Health Care
  • Exchange
  • SRPT Nasdaq
  • RGLS Nasdaq
  • Market Cap
  • SRPT N/A
  • RGLS N/A
  • IPO Year
  • SRPT 1997
  • RGLS 2012
  • Fundamental
  • Price
  • SRPT $20.28
  • RGLS $7.88
  • Analyst Decision
  • SRPT Buy
  • RGLS Buy
  • Analyst Count
  • SRPT 26
  • RGLS 6
  • Target Price
  • SRPT $70.92
  • RGLS $8.50
  • AVG Volume (30 Days)
  • SRPT 6.5M
  • RGLS 2.0M
  • Earning Date
  • SRPT 08-06-2025
  • RGLS 08-07-2025
  • Dividend Yield
  • SRPT N/A
  • RGLS N/A
  • EPS Growth
  • SRPT N/A
  • RGLS N/A
  • EPS
  • SRPT N/A
  • RGLS N/A
  • Revenue
  • SRPT $2,233,371,000.00
  • RGLS N/A
  • Revenue This Year
  • SRPT $26.87
  • RGLS N/A
  • Revenue Next Year
  • SRPT $3.15
  • RGLS N/A
  • P/E Ratio
  • SRPT N/A
  • RGLS N/A
  • Revenue Growth
  • SRPT 59.15
  • RGLS N/A
  • 52 Week Low
  • SRPT $18.30
  • RGLS $0.83
  • 52 Week High
  • SRPT $173.25
  • RGLS $8.35
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 20.82
  • RGLS 59.29
  • Support Level
  • SRPT $18.30
  • RGLS $8.03
  • Resistance Level
  • SRPT $22.98
  • RGLS $8.29
  • Average True Range (ATR)
  • SRPT 2.20
  • RGLS 0.14
  • MACD
  • SRPT -1.46
  • RGLS -0.15
  • Stochastic Oscillator
  • SRPT 8.90
  • RGLS 18.97

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: